Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Nov 16, 2022 1:07am
179 Views
Post# 35102190

RE:RE:RE:RE:RE:RE:RE:Roche experiences second failure in Alzheimer's disease

RE:RE:RE:RE:RE:RE:RE:Roche experiences second failure in Alzheimer's disease

westcoast1000 wrote: Matt said 6 to 9 months for news on a phase 3. In the past they have been clear there is no phase 3 without a partner. 

That seems pretty solid from my viewpoint. I think we can expect to hear about a partner within 6-9 months on two phase 3 trials. 

Of course, ithese words would most likely be smoke and mirrors, and easily dismissed as more of the same, if not for the spectacular results.

People have been disappointed for years with this company. But in retrospect, it was always going to be that way until they partnered, because this is an odd-ball approach to cancer treatment and an odd-ball company. (Perhaps I should have thought about that 10 years ago, but here we are now).

The latest results cannot be dismissed or ignored. They will carry the day if anything can. What alternatives do Roche or Pfizer have if they want to be in immuno-ocology, patient centered, safe, and build on their existing portfolios?

 

well said...

and
Good to get some actual timing comments out of ONC
 

<< Previous
Bullboard Posts
Next >>